The Council of Scientific and Industrial Research (CSIR) developed a scientifically approved herbal product called NBRMAP-DB. This is an anti-diabetic formulation, that has shown therapeutic efficacy for treating newly diagnosed type 2 diabetes. This drug was developed by CSIR with the help of its constituent laboratories which are Central Institute of Medicinal & Aromatic Plants (CSIR-CIMAP), Lucknow; and CSIR-National Botanical Research Institute (CSIR-NBRI), Lucknow. NBRMAP-DB was licensed to AIMIL Pharma Ltd, who are manufacturing and marketing it as BGR-34, across the country. In Delhi they further carried out the clinical study of BGR-34 and the trial was registered in the clinical trial registry of India (Registration number: CTRI/2016/11/007476).
The CCRAS in collaboration with Directorate General of Health Services, Ministry of Health & Family Welfare with the Integration of AYUSH (Ayurveda) component with NPCDCS (National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular diseases & Stroke ) has implemented and executed a programme that will cater healthcare services and reduce the burden of NCDs including Diabetes by combining the strength of Ayurveda and Yoga, in the identified districts of 3 states viz. Bhilwara (Rajasthan), Surendranagar (Gujarat) and Gaya (Bihar).
Via AYUSH-NPCDCS Clinic / Lifestyle Modification Clinics, developed for the prevention and management of selected NCDs via Ayurvedic intervention, Lifestyle Modifications and Yoga Advice, the aforementioned system is now successfully functional in 52 centers (49 CHCs and 3 District Hospitals) of all 3 districts listed.
The AYUSH82 formulation for diabetes was developed by CCRAS through the scientific process of drug development and commercialized for wider public use through the National Research Discovery Corporation (NRDC).